About Us

Our story

CimCure is a new generation company founded by its CSO in 2015, as a spin-off company of Amsterdam UMC. CimCure focuses on design and development of a novel class of active cancer vaccines.

Team

Diederik Engbersen, MSc

CEO

Diederik holds an MSc degree in medicine from Leiden University, Netherlands, and has more than 25 years of experience in the life science industry holding various international and executive positions in strategic marketing, R&D, business development and general management in both established as well as early stage and start up companies.

Prof. Arjan Griffioen, PhD

CSO

Arjan holds a PhD in medicine from Utrecht University, Netherlands. He is a key opinion leader in the field of angiogenesis. He was trained as an immunologist and published >250 peer-reviewed scientific publications. He is heading the Angiogenesis Laboratory, is director of the Graduate School of Oncology (OOA) and of the Master Oncology program of Amsterdam UMC and is Editor-in-Chief of the journal Angiogenesis that he founded.

Else Huijbers, PhD

Senior Scientist

Else holds a PhD in medicine from Uppsala University, Sweden. She was trained as a phamacist and has received several major grants from National and European sources. She presented the first proof-of-concept for using conjugate vaccines against the tumor vasculature.

Scientific Advisory Board

Prof. Ada Kruisbeek

Ada has a long-standing career as researcher at the NIH before becoming Head of the Department of Immunology of the Netherlands Cancer Institute and Professor of Immunology at the VU University of Amsterdam.

Later, she joined Crucell as Sr VP Research, founded DC-Prime and served as their CEO for many years. Currently, Ada is an advisor to DC-Prime and various other companies and foundations.

Prof. Roberto Pili

Roberto has a long-time career as physician-scientist with a large experience in the field of drug development in genitourinary malignancies.

Currently, Roberto is the Associate Dean for Cancer Research and Integrative Oncology, the Chief of Hematology and Oncology and Inaugural Director of the Center for Nutritional Sciences and Cancer Therapeutics at the Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, NY, USA.

Prof. Patrycja Nowak-Sliwinska

Patrycja is an expert in vascular biology and cancer and co-inventor of CimCure’s Technology. Her current expertise is in the design of combination therapies for the treatment of cancer.

Currently, she is Professor of Molecular Pharmacology at the School of Pharmaceutical Sciences at the University of Geneva, Switzerland.